Suramin sodium salt

≥98% (TLC)

Suramine sodium salt
Empirical Formula (Hill Notation):
CAS Number:
Molecular Weight:
Beilstein/REAXYS Number:
EC Number:
MDL number:
PubChem Substance ID:
Pricing and availability is not currently available.

Quality Level


≥98% (TLC)


H2O: >10 mg/mL

SMILES string




InChI key


Gene Information

human ... EGF(1950), FGF1(2246), P2RX1(5023), P2RY1(5028), PDGFA(5154), PLD1(5337)

Looking for similar products? Visit Product Comparison Guide

General description

Suramin is an antiparasitic drug, which blocks endothelial cell proliferation and increases tyrosine phosphorylation of many signalling proteins. It is associated with urticaria, paresthesias, vomiting and neurologic toxicity. Suramin is used to treat trypanosomiasis and onchocerciasis. It functions as an inhibitor of heparanase and also exhibits anti-AIDS (acquired immunodeficiency syndrome) property.


Suramin sodium salt has been used:
  • as a potent blocker of rat P2Y2 purinergic receptor
  • to study its effects on short circuit current (Isc) across strial marginal cells
  • to show its effects on initial burst of glial activity
  • to assess its neuroprotective potential in rats
  • as a purinoceptor inhibitor, to explore the mechanism of action of extracellular adenosine triphosphate (eATP)


100, 500 mg in poly bottle

Biochem/physiol Actions

Suramin is a polysulfonated naphthylurea anticancer agent that inhibits tumor cell proliferation. It inhibits the activity of topoisomerase II by blocking the binding of the enzyme to DNA. It′s antiangiogenic activity may be related to its ability to bind to and inhibit the activity of several growth factors, including FGFa, FGFb, and PGDF. It uncouples G-proteins from receptors. It is an broad spectrum antagonist at P2X and P2Y purinergic receptors. Suramin has well documented antiprotozoal and anthelmintic activity.

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Reactive blue 2, an antagonist of rat P2Y4, increases K+ secretion in rat cochlea strial marginal cells
Lee JHO, et al.
Hearing Research, 219(1-2), 66-73 (2006)
Antiparasitic agents
Principles and Practice of Pediatric Infectious Diseases (Fourth Edition), 1518-1545 (2012)
Liang Sun et al.
PLoS pathogens, 15(5), e1007760-e1007760 (2019-05-10)
Enterovirus A71 (EV-A71) is a non-polio neurotropic enterovirus with pandemic potential. There are no antiviral agents approved to prevent or treat EV-A71 infections. We here report on the molecular mechanism by which a novel class of tryptophan dendrimers inhibits (at...
Irene Kuepfer et al.
PLoS neglected tropical diseases, 6(8), e1695-e1695 (2012-09-13)
Assessment of the safety and efficacy of a 10-day melarsoprol schedule in second stage T.b. rhodesiense patients and the effect of suramin-pretreatment on the incidence of encephalopathic syndrome (ES) during melarsoprol therapy. Sequential conduct of a proof-of-concept trial (n = 60) and...
Gabriela M Rozanski et al.
The European journal of neuroscience, 37(3), 359-365 (2012-12-12)
Most dorsal root ganglion neuronal somata (NS) are isolated from their neighbours by a satellite glial cell (SGC) sheath. However, some NS are associated in pairs, separated solely by the membrane septum of a common SGC to form a neuron-glial...
EGF Signaling: Tracing Cancer's Path
Read More
Epigenetic modifications are thought to occur through two key interconnected processes—DNA methylation and the covalent modification of histones.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.